Cell-free fetal DNA (cffDNA) is available in the maternal circulation throughout pregnancy and can be used for noninvasive prenatal diagnosis including, determination of fetal sex, identification of specific single gene disorders, typing of fetal blood groups (RhD), paternity determination and potentially routine use for Down's syndrome (DS) testing of all pregnancies. I searched published literature on the PubMed and databases on Scopus interface systematically using keyword's cffDNA, noninvasive diagnosis, fetal DNA in the maternal serum. Reference lists from the papers were also searched. cffDNA representing only 3% of the total cell-free circulating DNA in early and rising to 12% in late pregnancy, clinical investigations has already demonstrated the potential advantage, such as improving safety, earlier diagnosis and comparative ease of testing using cffDNA technology. The discovery of cffDNA circulating in the maternal serum has opened the door to noninvasive prenatal diagnosis testing with novel clinical implications.
INTRODUCTION
In 1997, Lo et al identified cell-free fetal DNA (cffDNA) in the maternal serum circulation. This recommendation has generated research in the development of clinical applications based on evaluating of cffDNA for noninvasive diagnosis. 1 Nonetheless, invasive techniques of prenatal diagnosis, such as amniocentesis, cordocentesis and chorionic villus sampling (CVS), are precious and correlated with risks to the mother and the fetus; these procedures carry a risk of miscarriage of around 1%. 2, 3 Advances in molecular genetic have provided new tools for the genetic analysis of cffDNA isolated from maternal serum. 4 The cffDNA originates in trophoblast cells, therefore, fetal DNA fragments are released into maternal circulation after trophoblast degradation; apoptosis of fetal cells circulating in maternal blood may provide a minor source of cffDNA [5] [6] [7] and comprises around 3 to 6% of the total cffDNA in maternal circulation during early and late pregnancy respectively. 8 However, currently with development of 
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approaches, such as microfluidics digital polymerase chain reaction (PCR), reveals a higher than expected concentrations of fetal DNA around 10 to 12% of total DNA in maternal plasma. 9 The size of circulating cffDNA predominantly of short DNA fragments, 193 base pairs in length 10 and can be detected from the 4 weeks of gestation, 11 though only reliably from 7 weeks, and the concentration increases with gestational age with a sharp peak during the last 8 weeks of pregnancy. 8, 12 The half-life of cffDNA is 16 minutes and is undetectable 2 hours after delivery, therefore, rapidly cleared from the maternal circulation. 13 cffDNA may be detectable for several days. 14 Significantly, more fetal DNA is presence in maternal circulation during pregnancy as compared with the fetal DNA extracted from the cellular fraction of maternal blood.
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INVASIVE AND NONINVASIVE PRENATAL SCREENING TESTS
Current prenatal diagnosis relies on a combination of techniques, which falls into two categories: Noninvasive and invasive prenatal screening tests which are designed to detect those cases, which have a higher probability of fetal abnormality. There are many forms of prenatal diagnosis which are currently in use, such as amniocentesis and CVS, are invasive diagnostic techniques which are most widely accepted methods for obtaining fetal cells for genetic analysis. Both of these techniques are invasive and carry an associated risk of approximately 1% fetal loss. 16 Noninvasive techniques are used as screening tools and lack the predictive power to form diagnostic tests individually. Ultrasound examinations are routinely used to diagnose congenital defects, such as Down's syndrome. Maternal serum screening for fetal biomarkers is another noninvasive method for the measurement of fetal-specific proteins as an indicator for trisomy 21. 17 There are new technologies for the isolation of fetal cells from maternal blood. 18 After the discovery of fetal cells, it has been hypothesized that fetal nucleic acids may well also circulate in the maternal bloodstream. The presence of cffDNA in the maternal circulation was first discovered, by identification of a Y chromosome-specific sequence SRY.
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PRESENCE OF cffDNA IN THE MATERNAL CIRCULATION
The potential use of cffDNA in plasma or serum was first developed as a tool for molecular diagnosis of tumor DNA has been detected in the cancer patients. 19 The placenta has been well characterized as an invasive tissue. 20 Based on the hypothesis that the placenta has some cancer-like properties, therefore, we can be identifying cffDNA in the circulation of pregnant women. If cffDNA could be identified and isolated from maternal peripheral blood samples, it could potentially be used in prenatal screening of fetal anomalies. Use of cffDNA technology within existing specialist, clinical genetic services provide a valuable tool for earlier and safer determination of fetal sexlinked disorders. However, the availability of noninvasive tests using cffDNA could also lead to an increase to the ability in prenatal diagnosis testing and could influence the choices by parents to continue or terminations of pregnancy.
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ORIGIN OF cffDNA IN MATERNAL CIRCULATION
Fetal DNA originates from trophoblasts derived from the embryo 22 and representing only 3% of the total cell-free circulating DNA in early pregnancy rising to 6% in late pregnancy. 8 It is proposed that apoptosis is the main route by which stable DNA is released by cells into the circulation. 5 However, the precise mechanism of DNA release may also include the release of DNA by normal healthy lymphocytes. 23 Three possibilities mechanism discussed of DNA release: Fetal hematopoietic cells, the placenta and direct transfer of DNA molecules.
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CLINICAL APPLICATIONS FOR cffDNA
The majority of current investigations attended on cffDNA in the maternal circulation for clinical trials, specifically using quantitative real-time polymerase chain reaction amplification (Q-PCR) assays for prenatal screening 25 38 and achondroplasia can be detected. 39 The main limitation at present appears to be the availability of uniquely fetal gene sequences that identify and measure the presence of fetal DNA in both male and female fetuses.
FETAL SEX AND SEX-LINKED GENETIC DISORDERS DETERMINATION
There are extensively potential implementations for which cffDNA can be used for noninvasive prenatal diagnosis. The first application is the determination of fetal sex, by revealing genes instant on the Y chromosome in male fetuses. It must detect the sex-determining region Y (SRY), although a number of other Y chromosome-specific sequences present in multiple copies (DYS, DYZ and DAZ) per male genome have also been investigated. [40] [41] [42] This has been shown to be accurate at around 7 weeks or later gestation. 43 Fetal sexing can be used to consider risk for certain sex-linked hereditary disorders. Hemophilia is an X chromosome-linked familial disease, where males are affected with defective blood clotting factors, and females are carriers of the disease, therefore, optional choices at the parents to continue or terminations of pregnancy. 44 Fetal sex determination can also help in diagnosis, where there is genital obscurity, and in the management of metabolic conditions. 45 Several studies have demonstrated that there is a diagnostic sensitivity of 100% at 7 and 5 weeks of gestation using conventional and real-time PCR Table 1 .
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RhD GENOTYPING
The application cffDNA is a definition of fetal RhD blood group status in RhD-negative women, by detecting the paternally inherited RhD gene. This assessment supplies the basis for management of anti-D immunoglobulin as prophylaxis in pregnancies, where the fetus is confirmed as 
DETECTING OF SINGLE-GENE DISORDERS
The diagnosis-specific single gene disorders in families with a high-risk of an transmissible disorder, such as achondroplasia, Huntington's, myotonic dystrophy, congenital adrenal hyperplasia, hemophilia and β-thalassemia disease, frequently caused by a single-point mutation, requires the identification of changed genes in maternal circulation and can currently only be done to detect a gene alteration that is not present in the mother. 67 Achondroplasia is an autosomal dominant disorder, caused by point mutations within the FGFR3 gene, which accounts for more than 98% of the cases involved has been detected using cffDNA. 68 Huntington's disease appears to be a true Mendelian dominant because homozygote and heterozygote expressions are similar, generally associated with impressive changes in the area of the CAG trinucleotide repeats. Identification of Huntington's disease status was demonstrated to be highly accurate as early as 10 weeks of gestational age, although test sensitivity was reduced with greater expansion of CAG trinucleotide repeats.
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Myotonic dystrophy is an autosomal dominant disorder, associated with the changeable extension of a CTG trinucleotide repeat in the 3´untranslated region (3´-UTR) of the DM KINASE gene. In one study, paternally received expanded alleles revealed cffDNA in the maternal circulation. 72 Adrenal congenital, a group of recessive situations, resulted in enhanced production of androgens. It is detectable of intragenic polymorphic markers in intron 2 of the CYP21 gene. Using the analysis of fetal DNA in maternal blood can be detected recessive mutation congenital adrenal hyperplasia. 73 β-Thalassemia is a recessive blood disorder, caused by mutations in the globins' genes on chromosome 11 resulting in modifications to either the structure or production of hemoglobin, leading to chronic anemia. 74 A noninvasive experiment has also been advanced for β-thalassemia major. The assessment is based on a PCR assay designed to detect a paternally inherited CTTT deletion within the gene, which is the most conventional mutational cause of β-thalassemia. Allele-specific real-time PCR can be applied to mutations for β-thalassemia with 100% sensitivity and near-perfect specificity. 36, 75 Recently, Tsui et al by using the digital relative mutation dosage (RMD) approach recognized specifically genotypes of fetal that received a hemophilia mutation on chromosome X in plasma samples acquired at-risk carrying offspring women from as early as 11 weeks of gestation.
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ANEUPLOIDY IDENTIFICATION
Inaccuracies throughout the meiosis can begin aneuploidies, producing a number of gametes to gain a supplementary chromosome and change into trisomic. Attention has focused on aneuploidy, which is a notable cause of reproductive failure and congenital disease with unique remark to common chromosome disorders, such as trisomy 21 Down, trisomy 13 Patau and trisomy 18 Edward's syndromes as well as the sex chromosome aneuploidies XXY Klinefelter's, XYY, XXX, and X0 Turner's syndromes. 77 The most conventional invasive prenatal diagnostic technique for any aneuploidy is supplied by CVS or amniocentesis followed by karyotyping, although more recently, the easiest process of detecting an aneuploidy is to evaluate the relative amount of the target chromosome by selecting a region located on the chromosome and amplifying it by real-time PCR assay, and juxtaposing the product with that of other regions on different chromosome. 78 The majority common known aneuploidy consistent with life is Down's syndrome (DS). It was first characterized by Langdon Down in 1866 and linked to trisomy 21 in 1959 by Lejeune and Jacobs. 79 It is the largest part common chromosomal abnormality resulting in learning difficulties and mental defects. There is no racial predisposition, males and females are influenced in the almost the same ratios. 80 Several studies have declared that the levels of cffDNA heightened in aneuploidy conditions. 81 For example, in the DS pregnancies, cffDNA level increased of a 1.7-fold higher than to the serum controls. 82 Recently, Lo et al reported the use of multiplex massively parallel sequencing of cffDNA in maternal plasma detected trisomy 21 fetuses with 100% sensitivity and 97.9% specificity. 83 In another study, Chiu et al demonstrated the clinical effectiveness and practical feasibility of high-throughput DNA sequencing of singular chromosome 21 sequences in maternal serum with 79.1% sensitivity and 98.9% specificity. 84 Additional aneuploidies with recognized clinical significance consist of trisomy 18 and 13, both of which are frequently fatal within the first few months of life. Contemporary noninvasive approaches of prenatal diagnosis involve the use of screening technologies and procedures in order to evaluate risk of fetal aneuploidy, such as those based on ultrasound, the detection of serum biomarkers and at the finally using cffDNA can greatly reduce the number of pregnancies, which are subjected to testing by invasive methods. 85 Notwithstanding maternal serum cffDNA levels are increased in cases of trisomy 13, but not in trisomy 18.
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The other applications of cffDNA could be the paternity determinate of the fetus, by detection of systems DNA-STR (short tandem repeat) genotyping. The DNA-STR mostly has multiple alleles and can have high levels of diversity; that is, high heterozygosity. The systems DNA-STR genotyping is a standard for forensics and paternity testing. 87, 88 
CONCLUSION
The analysis of cffDNA in maternal serum and plasma is an operational region of research. The probability is that there will be a significant change in how we counsel women and couples who are considering prenatal screening and genetic diagnosis. The outstanding advantages of using cffDNA over conventional techniques of prenatal diagnosis are that the sampling method is noninvasive and, therefore, raises no risk to mother or child, and it can be pregnancy management. The relative ease of measurement of cffDNA levels in maternal plasma and serum has led to clinical applications to the detection of fetal aneuploidy, sex, Rh genotype and some single-gene disorders. Novel approaches, such as using microarray technology that is already available it is not difficult to imagine that amplified fetal nucleic acids will ultimately permit a noninvasive fetal genome to scan as part of routine prenatal screening. Moreover, the researcher's trends to progression clinical applications through the using of cffDNA, but implicated by several limitation's assessments in this field, including (a) the low concentrations of maternal serum cffDNA levels in earlier stage of gestation, (b) the occurrence of falsenegative/positive results in Rh genotyping and sex determination of the fetus, especially to the twin-gestation, (c) situations where both parents carry a mutant allele for recessively inherited monogenic disorders or for the diagnosis of fetal aneuploidy is more challenging and invasive prenatal diagnosis plays a crucial role here. Nevertheless, we hope that development in the new technologies will be capable in overcoming these limitations.
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